Summary of opinion: ZILBRYSQ,Zilucoplan, 14/09/2023, Positive
On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zilbrysq1, intended for the treatment of Myasthenia Gravis. The …